METHOXSALEN for Psoriasis: Side Effects & Safety Data
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
There are 8 adverse event reports in the FDA FAERS database where METHOXSALEN was used for Psoriasis.
Most Reported Side Effects for METHOXSALEN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Product use in unapproved indication | 334 | 51.7% | 115 | 76 |
| Condition aggravated | 39 | 6.0% | 11 | 10 |
| Pulmonary embolism | 37 | 5.7% | 7 | 21 |
| Disease progression | 34 | 5.3% | 12 | 3 |
| Infection | 33 | 5.1% | 28 | 3 |
| Off label use | 33 | 5.1% | 5 | 9 |
| Death | 32 | 5.0% | 31 | 3 |
| Hypotension | 27 | 4.2% | 3 | 6 |
| Chronic graft versus host disease | 23 | 3.6% | 4 | 0 |
| Graft versus host disease | 20 | 3.1% | 11 | 4 |
| Pyrexia | 20 | 3.1% | 2 | 10 |
| Acute graft versus host disease | 19 | 2.9% | 15 | 2 |
| Dyspnoea | 19 | 2.9% | 1 | 6 |
| Nausea | 19 | 2.9% | 2 | 5 |
| Sepsis | 19 | 2.9% | 12 | 5 |
Other Indications for METHOXSALEN
Graft versus host disease (113)
Chronic graft versus host disease (86)
Product used for unknown indication (72)
Acute graft versus host disease (64)
Cutaneous t-cell lymphoma (40)
Graft versus host disease in gastrointestinal tract (22)
Mycosis fungoides (19)
Acute graft versus host disease in skin (18)
Chronic graft versus host disease in skin (16)
Graft versus host disease in skin (16)
Other Drugs Used for Psoriasis
APREMILAST (76,127)
SECUKINUMAB (58,471)
ADALIMUMAB (56,634)
RISANKIZUMAB-RZAA (40,890)
ETANERCEPT (30,483)
USTEKINUMAB (21,763)
IXEKIZUMAB (16,569)
GUSELKUMAB (11,736)
CERTOLIZUMAB PEGOL (8,179)
METHOTREXATE (6,628)